PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008 2009
ACTIVITY HAS BEEN MODIFIED IN THE FOLLOWING WAYS FROM COP 2008:
+ Updated references to targets and budgets. The funds allocated for this activity will be used to procure
ARV drugs for 17,464 HIV positive pregnant women who are part of the total target to be reached with USG
support.
COP 2008
1. LIST OF RELATED ACTIVITIES
This activity relates to activities in ARV Drugs and all the activities listed in the HTXS program area.
2. ACTIVITY DESCRIPTION
This activity deals with the procurement and distribution of ARV drugs for patients supported by the
Emergency Plan. The objective of this drug procurement contract is to ensure reliable and uninterrupted
supplies of essential ARV commodities to Emergency Plan supported sites in Kenya. This activity will be
follow-on to the current USAID contract with the Mission for Essential Drugs and Supplies (MEDS), and the
contractor will be chosen through full and open competitive bidding at the mission level. The solicitation for
this activity is currently in process and a contractor will be awarded in early 2009 calendar year. The
contractor will forecast, procure, store, and distribute a limited formulary of ARV drugs for 17,464 HIV
positive pregnant women who will be among 190,000 patients reached in total by September 30, 2010. The
contractor will procure the required medicines and constantly communicate with suppliers for stock
availability, properly store and warehouse Emergency Plan stocks, distribute pharmaceuticals in a timely
and efficient manner to ensure continuity in patients' treatment, monitor quality assurance of the items
procured and distribution through a recognized quality control laboratory, and maintain appropriate records
on supplies for accurate program reporting, monitoring and evaluation. The key beneficiaries of this contract
will include public sector hospitals, faith based health facilities supported by PEPFAR, non-governmental
and community based organizations.
3. CONTRIBUTIONS TO OVERALL PROGRAM AREA
The procurement of ARVs will contribute to supporting 17,464 HIV positive pregnant women among
190,000 patients on treatment. This is 9.2% of the total number to be reached with ARV therapy.
4. LINKS TO OTHER ACTIVITIES
These activities will complement and link intimately with all activities listed in the ARV services program
area, as well as the Management Systems for Health/Strengthening Pharmaceutical Systems (MSH/SPS)
program in ARV drugs activity, KEMSA ARV drugs program activity, and KEMRI ARV drugs program
activity. The contractor will receive support from MSH/SPS, primarily in the area of improving quality control.
These activities will contribute directly to the result of achieving a full and uninterrupted supply of HIV/AIDS
related pharmaceuticals and commodities.
5. POPULATIONS BEING TARGETED
Populations targeted include people living with HIV/AIDS, private health care workers and faith-based
organizations.
6. EMPHASIS AREAS
The major emphasis area for this activity is commodity procurement, with minor emphasis areas being
training, logistics and linkages with other sector initiatives.
New/Continuing Activity: Continuing Activity
Continuing Activity: 14708
Continued Associated Activity Information
Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds
System ID System ID
14708 12537.08 U.S. Agency for To Be Determined 6917 3618.08 Mission
International Competitive
Development Procurement /
OI Drugs
12537 12537.07 U.S. Agency for To Be Determined 4291 3618.07 Mission
Table 3.3.01:
ACTIVITY UNCHANGED FROM COP 2008
This activity relates to activities in ARV Drugs, and all the partners listed in the Pediatric and Adult care and
Treatment program areas
This activity deals with the procurement and distribution of drugs for opportunistic infections (OI) for patients
supported by the Emergency Plan. The objective of this OI drug procurement contract is to ensure reliable
and uninterrupted supplies of essential OI commodities to Emergency Plan supported sites in Kenya. This
activity will be a follow-on to the current USAID commodity procurement contract with the Mission for
Essential Drugs and Supplies (MEDS). The contractor will be chosen through full and open competitive
bidding at the mission level. The solicitation for this activity is nearing completion and a contractor is
expected to be awarded in last quarter of the 2008 calendar year. The contractor will forecast, procure,
store, and distribute a limited formulary of IO drugs for 300,000 patients but a supply of cotrimoxazole for a
total of 600,000 HIV infected patients. Specifically, the contractor will be expected to 1) quantify OI drugs
required to meet the set target of 300,000 patients, and cotrimoxazole for 600,000 patients by September
30, 2010, 2) procure the required medicines and maintain communication with suppliers for stock
availability, 3) properly store and warehouse the Emergency Plan stocks, 4) distribute them in a timely and
efficient manner to ensure continuity in patients' treatment, 5) monitor quality assurance of the items
procured and distribution through a recognized quality control laboratory, and 6) maintain appropriate
records on supplies for accurate program reporting, monitoring and evaluation. The Government of Kenya
has also planned to procure some quantities of OI drugs but these will fall short of the national needs for
these commodities, hence the need for the USG to supplement the OI drug procurement. It is important to
note, however, that the USG OI procurement will be limited to critical commodities such as cotrimoxazole,
some anti-fungals and painkillers. It is the expectation of the USG team that both the Kenyan Government
and Global Fund will take their responsibility to procure more OI drugs to meet the country's needs. The key
beneficiaries of this contract will include public sector hospitals, faith based health facilities supported by
PEPFAR, non-governmental and community based organizations.
The procurement of OI drugs will contribute to supporting 300,000 patients on treatment, therefore USG
contribution accounting for 60% of OI care nationally.
This activity will complement and link closely with all activities listed in the ARV services program area, as
well as the Management Systems for Health/Strengthening Pharmaceutical Systems (MSH/SPS) project in
ARV drugs activity, KEMSA ARV drugs program activity, and CRS/AIDS Relief ARV drugs program activity.
Populations targeted include PLWHA, private and public health care workers.
6. KEY LEGISLATIVE ISSUES ADDRESSED
None
7. EMPHASIS AREAS
The major emphasis area for this activity is Commodity Procurement, with two minor emphasis areas being
training, and logistics.
Continuing Activity: 14709
14709 4119.08 U.S. Agency for To Be Determined 6917 3618.08 Mission
6998 4119.07 U.S. Agency for To Be Determined 4291 3618.07 Mission
4119 4119.06 U.S. Agency for Mission for 3210 240.06 $500,000
International Essential Drugs
Development and Supplies
Table 3.3.08:
1. LIST OF RELATED ACTIVITIES: this activity relates to activities in ARV Drugs and all the activities listed
in the HTXS and PDTX program areas.
2. ACTIVITY DESCRIPTION:
supplies of essential ARV commodities to Emergency Plan supported sites in Kenya. This activity will be a
follow-up on to the current USAID contract with the Mission for Essential Drugs and Supplies (MEDS). The
this activity is nearing completion and a contractor is expected to be awarded in last quarter of the 2008
calendar year. The contractor will forecast, procure, store, and distribute a comprehensive formulary of ARV
drugs sufficient to treat 190,000 patients, 25,000 of whom will be on second-line or alternate regimens.
Illustratively, some of the ARVs the contractor is expected to procure, will include, but not be limited to;
lamivudine 150mg/zidovudine 300mg/nevirapine 200mg FDC tabs as well as the individual formulations
where needed, abacavir 300mg tabs, didanosine 250/400mg tabs, efavirenz 600mg tabs, lopinavir
200mg/ritonavir 50mg tabs, tenofovir 300mg tabs, and stavudine 30mg based FDCs, if still recommended in
the national guidelines at that time. Also, the contractor will forecast, quantify, procure, store, and distribute
drugs purchased through Emergency Plan funds, including ARVs to meet the set target of 190,000 patients
by September 30, 2010. The contractor will procure the required medicines and constantly communicate
with suppliers for stock availability, properly store and warehouse Emergency Plan stocks, distribute
pharmaceuticals in a timely and efficient manner to ensure continuity in patients' treatment, monitor quality
assurance of the items procured and distribution through a recognized quality control laboratory, and
maintain appropriate records on supplies for accurate program reporting, monitoring and evaluation. The
key beneficiaries of this contract will include public sector hospitals, faith based health facilities supported
by PEPFAR, non-governmental and community based organizations.
3. CONTRIBUTIONS TO OVERALL PROGRAM AREA:
The procurement of ARVs will contribute to supporting 190,000 patients on treatment, therefore accounting
for 55% of the USG contribution to treatment nationally.
4. LINKS TO OTHER ACTIVITIES:
program in ARV drugs activity , KEMSA ARV drugs program activity , and KEMRI ARV drugs program
activity . These activities will contribute directly to the result of achieving a full and uninterrupted supply of
HIV/AIDS related pharmaceuticals and commodities.
5. POPULATIONS BEING TARGETED:
6. EMPHASIS AREAS:
Continuing Activity: 14711
14711 4118.08 U.S. Agency for To Be Determined 6917 3618.08 Mission
6997 4118.07 U.S. Agency for To Be Determined 4291 3618.07 Mission
4118 4118.06 U.S. Agency for Mission for 3210 240.06 $35,360,000
Table 3.3.15:
